Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer. [Estudio fase II de Ixabepilona y Trastuzumab versus Docetaxel y Trastuzumab en mujeres con cáncer de mama localmente avanzado y/o mestatásico con sobresexpresión de Her2].

Trial Profile

Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer. [Estudio fase II de Ixabepilona y Trastuzumab versus Docetaxel y Trastuzumab en mujeres con cáncer de mama localmente avanzado y/o mestatásico con sobresexpresión de Her2].

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Docetaxel; Ixabepilone; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2012 The trial status is recruiting in (Spain and France) and prematurely ended in (Italy) as reported by European Clinical Trials Database.
    • 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2012 Actual patient number 50 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top